Federated Hermes Inc. Lowers Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Federated Hermes Inc. decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 113,017 shares of the specialty pharmaceutical company’s stock after selling 15,188 shares during the period. Federated Hermes Inc. owned about 0.18% of Jazz Pharmaceuticals worth $12,062,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in JAZZ. Rise Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc raised its holdings in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares in the last quarter. GAMMA Investing LLC lifted its position in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares during the period. Gladius Capital Management LP bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $33,000. Finally, Cape Investment Advisory Inc. grew its position in shares of Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 292 shares during the period. Institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Robert W. Baird lowered their price objective on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Finally, StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.07.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $109.57 on Tuesday. The firm’s 50-day moving average price is $110.21 and its 200-day moving average price is $111.20. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $137.38. The company has a market cap of $6.91 billion, a PE ratio of 22.59, a PEG ratio of 1.31 and a beta of 0.57. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. As a group, analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.